Clinical Trials Directory

Trials / Completed

CompletedNCT01062737

Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis

Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
Sponsor
Laboratoires Expanscience S.A. · Industry
Sex
All
Age
45 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study aims to assess the long term (three years) ability of ASU (Avocado Soya unsaponifiable) to slow the decrease of radiographic JSW (Joint Space Width) in hip osteoarthritis (OA). This is a randomized, double blind, comparative, parallel group study versus placebo.

Detailed description

Inclusion criteria: Primary hip OA, fulfilling ACR criteria, patient over 45 y, painful \> 1 year, Lequesne's index \> or equal to 3, with minimum JSW at the target hip \> 1 mm and \< 4 mm on pelvic radiograph. Primary criterion of efficacy: The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader. Randomisation is stratified according JSW at baseline (\< 2,5 mm or \> or equal to 2,5 mm). Statistical analysis: The Full Analysis Set (FAS) is defined by patients with at least one baseline value and one post baseline value. The main analysis is scheduled on FAS using a Missing At Random (MAR)with a multiple model repeated measure (MMRM)to take in account missing value. SAP (Statistical Analysis Plan) schedule to analyse JSW change as quantitative variable using an ANCOVA and as qualitative variable (progressors defined as JSW loss upper than 0,5 mm) using Mantel Haentzel test.

Conditions

Interventions

TypeNameDescription
DRUGASU

Timeline

Start date
1999-12-01
Primary completion
2006-09-01
Completion
2006-09-01
First posted
2010-02-04
Last updated
2010-02-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01062737. Inclusion in this directory is not an endorsement.